Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Centogene stock logo
CNTG
Centogene
$0.39
-2.0%
$0.59
$0.36
$1.98
$10.56M-0.6763,745 shs71,204 shs
DermTech, Inc. stock logo
DMTK
DermTech
$0.62
+0.8%
$0.66
$0.57
$3.90
$21.63M2.53292,574 shs139,657 shs
Psychemedics Co. stock logo
PMD
Psychemedics
$2.55
-1.5%
$2.81
$2.06
$5.26
$14.81M0.6910,504 shs1,117 shs
Exagen Inc. stock logo
XGN
Exagen
$1.57
+11.3%
$1.56
$1.30
$3.92
$27.26M1.236,533 shs88,468 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Centogene stock logo
CNTG
Centogene
+2.05%-8.29%-38.87%-61.36%-50.13%
DermTech, Inc. stock logo
DMTK
DermTech
-3.28%-1.49%-6.77%-50.40%-76.34%
Psychemedics Co. stock logo
PMD
Psychemedics
+1.97%0.00%-8.48%-11.60%-51.77%
Exagen Inc. stock logo
XGN
Exagen
0.00%+1.45%-6.67%-32.37%-51.22%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Centogene stock logo
CNTG
Centogene
2.5602 of 5 stars
2.03.00.04.52.60.00.0
DermTech, Inc. stock logo
DMTK
DermTech
0.453 of 5 stars
3.00.00.00.00.00.01.3
Psychemedics Co. stock logo
PMD
Psychemedics
N/AN/AN/AN/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
4.5831 of 5 stars
3.55.00.04.50.64.20.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Centogene stock logo
CNTG
Centogene
N/AN/A$1.50284.62% Upside
DermTech, Inc. stock logo
DMTK
DermTech
2.00
Hold$2.38280.45% Upside
Psychemedics Co. stock logo
PMD
Psychemedics
N/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
3.00
Buy$6.00282.17% Upside

Current Analyst Ratings

Latest DMTK, XGN, PMD, and CNTG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/19/2024
DermTech, Inc. stock logo
DMTK
DermTech
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$0.63
4/19/2024
DermTech, Inc. stock logo
DMTK
DermTech
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$1.50
4/19/2024
DermTech, Inc. stock logo
DMTK
DermTech
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
3/5/2024
DermTech, Inc. stock logo
DMTK
DermTech
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$2.50 ➝ $1.50
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Centogene stock logo
CNTG
Centogene
$50.71M0.21N/AN/A$0.29 per share1.34
DermTech, Inc. stock logo
DMTK
DermTech
$15.30M1.41N/AN/A$1.67 per share0.37
Psychemedics Co. stock logo
PMD
Psychemedics
$22.10M0.67N/AN/A$1.15 per share2.22
Exagen Inc. stock logo
XGN
Exagen
$52.55M0.52N/AN/A$1.33 per share1.18

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Centogene stock logo
CNTG
Centogene
-$33.55MN/A0.00N/AN/AN/AN/A5/21/2024 (Estimated)
DermTech, Inc. stock logo
DMTK
DermTech
-$100.89M-$3.14N/AN/AN/A-659.57%-123.96%-67.94%5/16/2024 (Estimated)
Psychemedics Co. stock logo
PMD
Psychemedics
-$4.15M-$0.72N/AN/A-18.39%-48.68%-26.77%5/14/2024 (Estimated)
Exagen Inc. stock logo
XGN
Exagen
-$23.69M-$1.34N/AN/AN/A-45.08%-80.28%-36.27%5/13/2024 (Confirmed)

Latest DMTK, XGN, PMD, and CNTG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2024N/A
Exagen Inc. stock logo
XGN
Exagen
-$0.40N/A+$0.40N/AN/AN/A  
3/28/2024Q4 2023
Psychemedics Co. stock logo
PMD
Psychemedics
N/A-$0.16-$0.16-$0.16N/A$5.00 million
3/18/2024Q4 2023
Exagen Inc. stock logo
XGN
Exagen
-$0.41-$0.43-$0.02-$0.31$11.43 million$13.77 million      
2/29/2024Q4 2023
DermTech, Inc. stock logo
DMTK
DermTech
-$0.54-$0.56-$0.02-$0.56$4.05 million$3.92 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Centogene stock logo
CNTG
Centogene
N/AN/AN/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/A
Psychemedics Co. stock logo
PMD
Psychemedics
$0.2810.98%-8.04%N/A N/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Centogene stock logo
CNTG
Centogene
N/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
N/A
4.59
4.52
Psychemedics Co. stock logo
PMD
Psychemedics
N/A
1.45
1.45
Exagen Inc. stock logo
XGN
Exagen
0.85
4.02
4.02

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Centogene stock logo
CNTG
Centogene
9.94%
DermTech, Inc. stock logo
DMTK
DermTech
20.45%
Psychemedics Co. stock logo
PMD
Psychemedics
32.07%
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Centogene stock logo
CNTG
Centogene
1.93%
DermTech, Inc. stock logo
DMTK
DermTech
5.10%
Psychemedics Co. stock logo
PMD
Psychemedics
24.00%
Exagen Inc. stock logo
XGN
Exagen
36.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Centogene stock logo
CNTG
Centogene
44427.08 millionN/ANot Optionable
DermTech, Inc. stock logo
DMTK
DermTech
20634.62 million32.86 millionOptionable
Psychemedics Co. stock logo
PMD
Psychemedics
1165.81 million4.41 millionNot Optionable
Exagen Inc. stock logo
XGN
Exagen
17417.36 million10.97 millionOptionable

DMTK, XGN, PMD, and CNTG Headlines

SourceHeadline
Exagen to Announce First Quarter 2024 Results on May 13, 2024Exagen to Announce First Quarter 2024 Results on May 13, 2024
finance.yahoo.com - April 30 at 5:42 PM
Exagen Inc. Announces Changes to the Board of DirectorsExagen Inc. Announces Changes to the Board of Directors
globenewswire.com - April 26 at 8:30 AM
Exagen receives consent for 20 MW UK batteryExagen receives consent for 20 MW UK battery
energyglobal.com - April 26 at 5:08 AM
Exagen Inc Ordinary SharesExagen Inc Ordinary Shares
morningstar.com - April 16 at 11:11 PM
Analyst Estimates: Heres What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual ReportAnalyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual Report
finance.yahoo.com - March 21 at 9:07 AM
Exagen Inc. (XGN) Q4 2023 Earnings Call TranscriptExagen Inc. (XGN) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 20 at 6:05 PM
Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth InitiativesBuy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives
markets.businessinsider.com - March 20 at 6:05 PM
Exagen Full Year 2023 Earnings: Beats ExpectationsExagen Full Year 2023 Earnings: Beats Expectations
finance.yahoo.com - March 20 at 6:05 PM
Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call TranscriptExagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 19 at 10:03 AM
Exagen’s Strong Q4 Performance and Positive Outlook Justify Buy RatingExagen’s Strong Q4 Performance and Positive Outlook Justify Buy Rating
markets.businessinsider.com - March 19 at 12:03 AM
Heres what to expect from Exagens earningsHere's what to expect from Exagen's earnings
markets.businessinsider.com - March 18 at 2:02 PM
Exagen reports Q4 resultsExagen reports Q4 results
msn.com - March 18 at 2:02 PM
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023
investorplace.com - March 18 at 2:00 PM
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue EstimatesExagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
zacks.com - March 18 at 10:25 AM
Anticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See UpticksAnticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See Upticks
msn.com - March 18 at 9:01 AM
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 ResultsExagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
globenewswire.com - March 18 at 8:00 AM
XGN Apr 2024 2.500 putXGN Apr 2024 2.500 put
finance.yahoo.com - March 18 at 4:01 AM
Insider Selling: Exagen Inc. (NASDAQ:XGN) CFO Sells 12,784 Shares of StockInsider Selling: Exagen Inc. (NASDAQ:XGN) CFO Sells 12,784 Shares of Stock
insidertrades.com - March 16 at 11:14 AM
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor ForumExagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
finance.yahoo.com - March 8 at 11:31 AM
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor ForumExagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
globenewswire.com - March 8 at 9:00 AM
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
globenewswire.com - March 7 at 4:05 PM
Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain StockDespite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock
finance.yahoo.com - February 6 at 12:57 PM
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceExagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
finance.yahoo.com - January 30 at 8:51 PM
Exagen secures planning approval for 500MW battery storage projectExagen secures planning approval for 500MW battery storage project
edie.net - January 15 at 12:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Centogene logo

Centogene

NASDAQ:CNTG
Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services. In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
DermTech logo

DermTech

NASDAQ:DMTK
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.
Psychemedics logo

Psychemedics

NASDAQ:PMD
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, Fentanyl, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Dallas, Texas.
Exagen logo

Exagen

NASDAQ:XGN
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.